9920 Jefferson Boulevard
89 articles with NantKwest
Researchers are continuing to develop next-generation therapeutics and oral vaccines that could overcome some vaccine hesitancy. Here are some of the top producers.
Simply put, an antibody is a large, Y-shaped blood protein produced by plasma cells that the immune system uses to take down pathogens like bacteria – and of course, viruses like SARS-CoV-2.
All Three Independent Proxy Advisory Firms – ISS, Glass Lewis and Egan-Jones – Recommend NantKwest Stockholders Vote “FOR” the Pending Merger With ImmunityBio
The NantKwest Special Committee and the NantKwest Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 8, 2021 at 9:30 a.m. Pacific Time
ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity
FDA authorized the expansion of the active Phase 1 COVID-19 vaccine trial and a second trial to test a novel combination of T-cell-based hAd5 subcutaneous prime vaccine with a room-temperature oral or sublingual boost, to induce comprehensive immune protection through CD4+ and CD8+ T cells to both Spike (S) and Nucleocapsid (N) antigens, as well as generate systemic and mucosal antibodies
NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials
Pivotal QUILT 88 trial based on combination immunotherapy of “Cancer Moonshot” strategy; early indications of increased survival rate for pancreatic cancer patients with no other approved treatment options In initial Cancer Moonshot QUILT trials of haNK and avelumab (PD-L1 checkpoint inhibitor) completed in 2019, median overall survival rate more than doubled compared to historical controls (eight months versus three months)
NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021
NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39 th Annual J.P. Morgan Healthcare Conference on January 13, 2021
Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immunotherapy platforms
Shares of NantKwest were up more than 27% in premarket trading after the company announced a stock-for-stock reverse merger with privately-held ImmunityBio.
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced its participation in the virtual 32 nd Annual Piper Sandler Healthcare conference, which takes place December 1-3, 2020. NantKwest Executive Chairman Patrick Soon-Shiong, M.D., and Chief Executive Officer Rich Adcock will parti
ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study
First two cohorts fully enrolled; Low dose cohort reports no serious adverse events (SAE), high dose cohort safety analysis ongoing Subject screening is ongoing for Phase I expansion cohorts Phase 2 / 3 hAd5 COVID-19 trial in design
10/30/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Experienced Six Sigma healthcare executive bolsters leadership team at key juncture; will work closely with Dr. Patrick Soon-Shiong who will serve as Executive Chairman
ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Second-Generation COVID-19 Vaccine Candidate Delivering Both Spike and Nucleocapsid of SARS-CoV-2
First patient receives ImmunityBio’s second-generation hAd5 COVID vaccine, delivering both outer S (spike) protein and inner N (nucleocapsid) leading to potential long-term T cell and antibody immunity to the SARS-CoV-2 virus
NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial; Opens Study to Patients Who Have Failed All Approved Standards of Care
Third cohort added to independently evaluate the efficacy of NantKwest’s PD-L1 t-haNK natural killer cells plus ImmunityBio’s IL-15 superagonist Anktiva™ (N-803) in third-line or greater therapy for patients with locally advanced or metastatic pancreatic cancer. Two other cohorts for first-line maintenance and second-line randomized against standards of care chemotherapy. 40 patients are currently enrolled in or being evaluated for the Phase 2
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman and CEO, will present at the virtual Jefferies Cell Therapy Summit on Tuesday, October 6, 2020 at 12:50 PM ET. The conference presentation will be available on the NantKwest website, NantKwes
NantKwest Announces Closing of $90.7 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, announced today the closing of its previously announced underwritten public offering of an aggregate of 8,521,500 shares of its common stock (4,811,500 shares at a price to the public of $9.50 per share and 3,710,000 shares at a price of $12.12 per share to NantKwest’s chairman,
NantKwest, Inc., a clinical-stage, natural killer cell-based therapeutics company, announced the pricing of an underwritten public offering of an aggregate of 7,410,000 shares of its common stock.
NantKwest, Inc., a clinical-stage, natural killer cell-based therapeutics company, announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested
NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested NantKwest’s antibody-targeted NK cell line, haNK, which is engineered for increased antibody-dependent cell-mediated cytotoxicity and activation, showed increased resistance to hypoxic conditions as seen in suppressive tumor microenvironments N
NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020 at 4:30 pm ET. The presentation will be webcast live and can be accessed through the NantKwest and ImmunityBio websites, NantKwest.com and ImmunityBio.com . An archived replay will be available on the